Connect Biopharma Holdings Limited
CNTBNASDAQHealthcare● Active
$2.20
+$0.03(+1.38%)
Market Cap$138520477
P/E Ratio—
52W High$3.82
52W Low$0.77
Connect Biopharma Holdings Limited (CNTB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CNTB · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.06M | $26.03M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.06M | $26.03M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $37.80M | $29.26M | $53.00M | $96.63M | $80.50M |
| G&A Expenses | $20.34M | $19.23M | $16.05M | $20.81M | $19.01M |
| Total Operating Expenses | $58.14M | $48.48M | $69.06M | $119.32M | $98.11M |
| Operating Income | ($58.07M) | ($22.45M) | ($69.06M) | ($119.32M) | ($98.11M) |
| Operating Margin %(computed) | — | -86.24% | — | — | — |
| Interest Income | $2.27M | $4.45M | $0.01M | $1.56M | $0.10M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.02M | $0.01M |
| Income Before Tax | ($55.28M) | ($15.40M) | ($61.99M) | ($117.79M) | ($202.00M) |
| Income Tax Expense | $0.20M | $0.22M | $0.12M | $0.30M | $0.27M |
| Net Income | ($55.48M) | ($15.63M) | ($62.11M) | ($118.09M) | ($202.27M) |
| Net Margin %(computed) | — | -60.03% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.00 | $-0.28 | $-1.08 | $-14.50 | $-25.00 |
| Wtd Avg Shares | 55.66M | 55.21M | 55.07M | 55.04M | 52.27M |
| EBITDA | ($57.37M) | ($21.79M) | ($68.34M) | ($116.74M) | ($201.36M) |
| EBITDA Margin %(computed) | — | -83.71% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Connect Biopharma Holdings Limited data
About Connect Biopharma Holdings Limited (CNTB) Income Statement
Connect Biopharma Holdings Limited (CNTB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CNTB reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.06B) — a net profit margin of -86687.50%.
Frequently asked questions
CNTB · 4 questionsConnect Biopharma Holdings Limited (CNTB) reported revenue of $0.00B for 2025, down 99.8% year-over-year.
CNTB revenueCNTB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09